Young smiling boy
gray picture on left of breadcrumbs
 > Home  > Medical  > conclusions  > m

References: M

  • MacFarlane, J. G., J. M. Cleghorn, G. M. Brown, and D. L. Streiner. 1991. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: A preliminary study. Biol. Psychiatry 30:371-376.
  • Madison, L. S., T. E. Wells, T. E. Fristo, and C. G. Benesch. 1986. A controlled study of folic acid treatment in 3 fragile X syndrome males. J. Dev. Behav. Pediatr. 7:253-256.
  • Malhotra, S., and P. J. Santosh. 1998. An open clinical trial of buspirone in children with attention deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 37:364-371.
  • Malone, R. P., R. Sheikh, and J. M. Zito. 1999. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr. Services 50:171-174.
  • Manheim, D., L. Paalzow, and B. Hokfelt. 1982. Plasma clonidine in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension. Clin. Pharmacol. Ther. 31:445-451.
  • Manos, M. J., E. J. Short, and R. L. Findling. 1999. Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 38:813-819.
  • March, J. S., J. Biederman, R. Wolkow, A. Safferman, J. Mardekian, E. H. Cook, N. R. Cutler, R. Dominguez, J. Ferguson, B. Muller, R. Riesenberg, M. Rosenthal, F. R. Sallee, K. D. Wagner, and H. Steiner. 1998. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial [see comments] [published erratum appears in JAMA 283:1293, 2000]. JAMA 280:1752-1756.
  • Markowitz, P. I. 1992. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: A preliminary study. J. Clin. Psychopharmacol. 12:27-31.
  • Martin, A., K. Koenig, L. Scahill, and J. Bregman. 1999. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J. Child Adolesc. Psychopharmacol. 9:99-107.
  • Massand, P., S. Gupta, and M. Dewan. 1991. Suicidal ideation related to fluoxetine treatment [letter]. N. Engl. J. Med. 324:420.
  • Mayes, S. D., D. L. Crites, E. O. Bixler, F. J. Humphrey, and R. E. Mattison. 1994. Methylphenidate and ADHD: Influence of age, IQ and neurodevelopmental status. Dev. Med. Child Neurol. 36:1099-1107.
  • McClain, L. D., G. F. Carl, and W. F. Bridges. 1975. Distribution of folic acid coenzymes and folate dependent enzymes in mouse brain. J. Neurochem. 24:719-722.
  • McConville, B. J., L. A. Arvanitis, P. T. Thyrum, C. Yeh, L. A. Wilkinson, R. O. Chaney, K. D. Foster, M. T. Sorter, L. M. Friedman, K. L. Brown, and J. E. Heubi. 2000. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J. Clin. Psychiatry 61:252-260.
  • McDougle, C. J., J. P. Holmes, M. R. Bronson, G. M. Anderson, F. R. Volkmar, L. H. Price, and D. J. Cohen. 1997. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study [see comments]. J. Am. Acad. Child Adolesc. Psychiatry 36:685-693.
  • McDougle, C. J., J. P. Holmes, D. C. Carlson, D. H. Pelton, D. J. Cohen, and L. H. Price. 1998. A double blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry 55:633-641.
  • McElroy, S. L., and E. Weller. 1997. Psychopharmacological treatment of bipolar disorder across the life span. In S. L. McElroy (ed.), Psychopharmacology across the life span. Washington, D.C.: American Psychiatric Press, pp. 31-85.
  • Mendels, J., A. Kiev, and L. F. Fabre. 1999. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress. Anxiety 9:54-60.
  • Mezzacappa, E., R. Steingard, D. Kindlon, J. P. Saul, and F. Earls. 1998. Tricyclic antidepressants and cardiac autonomic control in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 37:52-59.
  • Miller, L. J., D. N. McIntosh, J. McGrath, V. Shyu, M. Lampe, A. K. Taylor, F. Tassone, K. Neitzel, T. Stackhouse, and R. J. Hagerman. 1999. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: A preliminary report. Am. J. Med. Genet. 83:268-279.
  • Milne, D. B., W. K. Canfield, J. R. Mahalko, and H. H. Sandstead. 1984. Effect of oral folic acid supplements on zinc, copper and iron absorption and excretion. Am. J. Clin. Nutr. 39:535-539.
  • Moffatt, M. E. 1997. Nocturnal enuresis: A review of the efficacy of treatments and practical advice for clinicians. J. Dev. Behav. Pediatr. 18:49-56.
  • Mondadori, C. 1993. The pharmacology of the nootropics: New insights and new questions. Behav. Brain Res. 59:1-9.
  • ---. 1994. In search of the mechanism of action of the nootropics: New insights and potential clinical implications. Life Sci. 55:2171-2178.
  • MTA Cooperative Group. 1999a. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry 56:1073-1086.
  • ---. 1999b. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 56:1088-1096.
  • Murphy, M. A., and R. J. Hagerman. 1992. Attention deficit hyperactivity disorder in children: Diagnosis, treatment and followup. J. Pediatr. Health Care 6:2-11.
  • Musumeci, S. A., R. Ferri, M. Elia, S. Del Gracco, C. Scuderi, and M. C. Stefanini. 1996. Normal respiratory pattern during sleep in young fragile X-syndrome patients [letter]. J. Sleep Res. 5:272.
  • Musumeci, S. A., R. J. Hagerman, R. Ferri, P. Bosco, K. Dalla Bernardina, C. A. Tassinari, G. B. DeSarro, and M. Elia. 1999. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40:1092-1099.
     

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields.

*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website.

The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 
back to homehow to navigatesite map creditsprivacycontact usdisclaimer

© copyright 1998-2008 NFXF
 
Medication can be important in the treatment of fragile X related behavior problems
TELL A FRIEND